Search results
Results From The WOW.Com Content Network
Domperidone, sold under the brand name Motilium among others, is a dopamine antagonist medication which is used to treat nausea and vomiting and certain ...
Deudomperidone (developmental code name CIN-102; also known as deuterated domperidone) is a dopamine antagonist medication which is under development in the United States for the treatment of gastroparesis. [1] [2] [3] It acts as a selective dopamine D 2 and D 3 receptor antagonist and has peripheral selectivity.
Dopamine receptor flow chart. Dopamine receptors are all G protein–coupled receptors, and are divided into two classes based on which G-protein they are coupled to. [1] The D 1-like class of dopamine receptors is coupled to Gα s/olf and stimulates adenylate cyclase production, whereas the D 2-like class is coupled to Gα i/o and thus inhibits adenylate cyclase production.
Dopamine receptors are a class of G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS) and are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation of neuroendocrine signaling.
Domperidone – a dopamine D 2 receptor antagonist used as an antiemetic, gastroprokinetic agent, and galactogogue; Dopamine – a non-selective dopamine and adrenergic receptor agonist used as a cardiac stimulant and positive inotropic agent
ATC code A03 Drugs for functional gastrointestinal disorders is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Domperidone (branded as Motilium) is widely available in in the UK without prescription from pharmacies, but this is not made clear. EnglishBriarRose ( talk ) 04:22, 5 January 2013 (UTC) [ reply ] A discussion of how it is used in the UK in regards brain tumour treatment would be useful.
In 2001, the FDA changed the labeling requirements for droperidol injection to include a Black Box Warning, citing concerns of QT prolongation and torsades de pointes.The evidence for this is disputed, with 9 reported cases of torsades in 30 years and all of those having received doses in excess of 5 mg. [9] QT prolongation is a dose-related effect, [10] and it appears that droperidol is not a ...